🟡 Medium ImpactPharma
Granules receives 4 USFDA observations for US facility
Granules receives 4 USFDA observations for US facility. The USFDA raised four Form-483 observations following an inspection of Granules’ manufacturing plant in the US. These observations highlight compliance issues that may impact drug approvals and exports. Granules must respond with corrective actions to avoid regulatory escalation.
📊 STOCKS: GRANULES | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA
#USFDA#compliance#pharma#inspection
Stocks mentioned
⚠️ This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.
Next article
south west pinnacle empanelled by oil →Trade smarter on NSE
Live option chains, FII flows, PCR, AI analysis — for NIFTY, BANKNIFTY & 200+ F&O stocks.
Start for ₹1 →